<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02724670</url>
  </required_header>
  <id_info>
    <org_study_id>M-base Pro 1.0</org_study_id>
    <nct_id>NCT02724670</nct_id>
  </id_info>
  <brief_title>Study of MR-based IGRT for Prostate Cancer</brief_title>
  <acronym>M-basePro</acronym>
  <official_title>Single-arm Phase II Study of MR(Magnetic Resonance Imaging)-Based Image-guided Radiotherapy for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MR (Magnetic Resonance Imaging) - based IGRT (image-guided radiotherapy) for patients with
      prostate carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single arm, phase II study, MR (Magnetic Resonance Imaging) - based IGRT (Image-guided
      radiotherapy) of prostate cancer.

      Primary endpoint: Grade 2+ GI (gastrointestinal) and genitourinary (GU) toxicity after 2
      years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">September 2028</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>G2+gastrointestinal and genitourinary toxicity at 2 years</measure>
    <time_frame>Total trial treatment duration: 4 years, Duration for individual patient:Study treatment 9 months, Follow-up: 2 years for primary endpoint</time_frame>
    <description>Number of participants with G2+-treatment-related genitournary and gastrointestinal adverse events assessed by CTCAE v4.0 and RTOG at 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term GU-GI toxicity</measure>
    <time_frame>10 years after treatment</time_frame>
    <description>Measurement of treatment-related genitournary and gastrointestinal adverse events assessed by CTCAE v4.0 and RTOG at 10 years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Radiation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>IGRT 5x 2Gy/week, total dose: 78 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IGRT</intervention_name>
    <description>MR-based IGRT</description>
    <arm_group_label>Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven prostate cancer

          -  indication for curative treatment

          -  ECOG performance scale 0-2

          -  Informed consent

        Exclusion Criteria:

          -  contraindications for curative treatment

          -  age&lt;18year

          -  previous pelvic radiotherapy or prostatic treatment like TURP (transurethral resection
             of prostate), HIFU (high intensity focused ultrasound)

          -  serious comorbidity leading to inability for IGRT (image-guided radiotherapy)

          -  contraindications for MRI (Magnetic Resonance Imaging)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt-Christian Müller, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, University of Tübingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arndt-Christian Müller, Dr.</last_name>
    <phone>497071/2986142</phone>
    <email>Arndt-Christian.Mueller@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Zips, Prof.</last_name>
    <phone>497071/2982165</phone>
    <email>Daniel.Zips@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Müller Arndt-Christian</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arndt-Christian Müller</last_name>
      <phone>070712986143</phone>
      <email>arndt-christian.mueller@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2016</study_first_submitted>
  <study_first_submitted_qc>March 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2016</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Arndt-Christian Mueller</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

